Investment Summary

Toyoda Gosei Invests In Synspective

On June 20, 2024, Toyoda Gosei invested in aerospace company Synspective

Investment Highlights
  • This is Toyoda Gosei’s 1st transaction in the Aerospace sector.
  • This is Toyoda Gosei’s 6th transaction in Japan.

Investment Summary
Date 2024-06-20
Target Synspective
Sector Aerospace
Investor(s) Toyoda Gosei
Deal Type Growth Capital

Target

Synspective

Tokyo, Japan
website
Synspective develops and operates small SAR satellites2 and provides solutions based on satellite data analysis. Its business covers from satellite development to operation and proposals for solutions to problems using the obtained observational data. SAR satellites use radio waves (microwaves) of the wavelength range that can penetrate clouds, and so ground data can be obtained even during inclement weather and at night. Synspective was formed in 2018 and is based in Tokyo, Japan.

Search 195,272 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Toyoda Gosei

Kiyosu, Japan

website

Category Company
Founded 1949
Sector Automotive
Employees39,511
Revenue 830.2B JPY (2022)
DESCRIPTION

Toyoda Gosei Co. is a specialty manufacturer of rubber and plastic automotive parts. Today, the Toyoda Gosei Group provides a variety of high-quality products internationally, with a network of approximately 100 plants and offices in 18 countries and regions. Through its flexible, integrated global supply system and leading-edge technologies, Toyoda Gosei aims to grow as a global company that acts flexibly and swiftly in today’s dramatically changing business environment, delivering the highest levels of satisfaction to customers worldwide through safety, comfort, well-being and the environment. Toyoda Gosei was founded in 1949 and is based in Kiyosu, Japan.

DEAL STATS #
Overall 6 of 6
Sector (Aerospace) 1 of 1
Type (Growth Capital) 1 of 1
Country (Japan) 6 of 6
Year (2024) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-04 Craif

Tokyo, Japan

Craif develops and sells test kits that can easily and highly sensitively detect the risks of seven types of cancer, including pancreatic and lung cancer, as early as cancer stage 1. These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect. Craif is based in Tokyo.

Buy -
Mergr

Product

Company

Legal